Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody

Both radionuclide imaging and near-infrared fluorescent (NIRF) imaging have a high sensitivity to detect tumors in vivo. The combination of these modalities using dual-labeled antibodies may allow both preoperative and intraoperative tumor localization and may be used in image-guided surgery to ensure complete resection of tumor tissue. Here, we evaluated the potential of dual-modality imaging of prostate cancer with the monoclonal antibody D2B, directed against an extracellular domain of prostate-specific membrane antigen (PSMA). For these studies, D2B was labeled both with 111In and with the NIRF dye IRDye800CW. Methods: D2B was conjugated with N-hydroxysuccinimide-IRDye800CW and p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) and subsequently radiolabeled with 111In. For biodistribution and NIRF imaging, 111In-DTPA-D2B-IRDye800CW (2 μg, 0.55 MBq/mouse) was injected intravenously into BALB/c nude mice with subcutaneous PSMA-expressing LNCaP tumors (right flank) and PSMA-negative PC3 tumors (left flank). The biodistribution was determined at 1, 2, 3, and 7 d after injection. In addition, micro-SPECT/CT and NIRF imaging with 111In-DTPA-D2B-IRDye800CW (3 μg, 8.5 MBq/mouse) was performed on mice with intraperitoneally growing LS174T-PSMA tumors. Results: 111In-DTPA-D2B-IRDye800CW specifically accumulated in subcutaneous PSMA-positive LNCaP tumors (45.8 ± 8.0 percentage injected dose per gram at 168 h after injection), whereas uptake in subcutaneous PSMA-negative PC3 tumors was significantly lower (6.6 ± 1.3 percentage injected dose per gram at 168 h after injection). Intraperitoneal LS174T-PSMA tumors could be visualized specifically with both micro-SPECT/CT and NIRF imaging at 2 d after injection, and the feasibility of image-guided resection of intraperitoneal tumors was demonstrated in this model. Conclusion: Dual-labeled 111In-DTPA-D2B-IRDye800CW enables specific and sensitive detection of prostate cancer lesions in vivo with micro-SPECT/CT and NIRF imaging. In addition to preoperative micro-SPECT/CT imaging to detect tumors, NIRF imaging enables image-guided surgical resection. These preclinical findings warrant clinical studies with 111In-DTPA-D2B-IRDye800CW to improve tumor detection and resection in prostate cancer patients.

[1]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[2]  E. Rosenthal,et al.  Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment , 2007, Cancer biology & therapy.

[3]  Adah Almutairi,et al.  Low power, biologically benign NIR light triggers polymer disassembly. , 2011, Macromolecules.

[4]  Hisataka Kobayashi,et al.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. , 2011, Bioconjugate chemistry.

[5]  Tessa Buckle,et al.  Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. , 2011, European urology.

[6]  G. Andriole.  Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer–Specific Mortality: Stephenson AJ, Eggener SE, Hernandez AV, et al (Cleveland Clinic, OH; Univ of Chicago Med Ctr, IL; et al) Eur Urol 65:675-680, 2014 § , 2014 .

[7]  Markus Graefen,et al.  Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. , 2014, European urology.

[8]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[9]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[10]  P. Scardino,et al.  Prognostic significance of location of positive margins in radical prostatectomy specimens. , 2007, Urology.

[11]  Victor Reuter,et al.  Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. , 2003, The Journal of urology.

[12]  Nynke S. van den Berg,et al.  Sentinel Lymph Node Biopsy for Prostate Cancer: A Hybrid Approach , 2013, The Journal of Nuclear Medicine.

[13]  D. M. Olive,et al.  A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. , 2007, Analytical biochemistry.

[14]  G. V. van Dongen,et al.  Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets , 2011, EJNMMI research.

[15]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  E. Rosenthal,et al.  Assessment of Bevacizumab Conjugated to Cy5.5 for Detection of Head and Neck Cancer Xenografts , 2008, Technology in cancer research & treatment.

[17]  Philip S Low,et al.  Development of tumor-targeted near infrared probes for fluorescence guided surgery. , 2013, Bioconjugate chemistry.

[18]  Tiancheng Liu,et al.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[19]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[20]  S. Cingarlini,et al.  Apical Transport and Folding of Prostate-specific Membrane Antigen Occurs Independent of Glycan Processing* , 2006, Journal of Biological Chemistry.

[21]  M. Pomper,et al.  Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. , 2011, Angewandte Chemie.

[22]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[23]  W. Oyen,et al.  ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model , 2010, The Journal of Nuclear Medicine.

[24]  V. Chernomordik,et al.  Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging , 2008, Clinical Cancer Research.

[25]  Michael W Kattan,et al.  Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. , 2014, European urology.